https://www.selleckchem.com/products/ptc-028.html
3; Cochrane Collaboration) is used for the meta-analysis. Two independent reviewers will assess the risk of bias of the included studies at study level. It is hypothesized that metformin use at the post-AMI is associated with decreased risk of cardiovascular disease and death in patients with T2DM. This study expects to provide credible and scientific evidence for the efficacy and safety of metformin on cardiovascular outcomes after AMI in patients with T2DM. 10.17605/OSF.IO/S3MBP. 10.17605/OSF.IO/S3MBP. A lot of research evidence shows
Like
Comment
Share
